BIO vs. TECH: Bio-Rad Laboratories vs. Bio-Techne Stock Comparison
How do Bio-Rad Laboratories (BIO) and Bio-Techne (TECH) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Bio-Rad Laboratories (BIO) and Bio-Techne (TECH) are both classified in the Life Sciences Tools & Services sub-industry within the broader Life Sciences Tools & Services industry, placing them in the closest GICS peer bucket.
| Profile Item | BIO | TECH |
|---|---|---|
| Name | Bio-Rad Laboratories Inc. | Bio-Techne Corp. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| GICS Sub-Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| Market Capitalization | 10.26 billion USD | 11.43 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | February 27, 1980 | February 9, 1989 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | BIO | TECH |
|---|---|---|
| Total Return (1Y) | 28.31% | 27.56% |
| Total Return (3Y, Annualized) | 8.52% | 9.11% |
| Total Return (5Y, Annualized) | -11.74% | -9.91% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | BIO | TECH |
|---|---|---|
| Volatility (1Y, Annualized) | 36.50% | 43.08% |
| Beta (5Y) | 1.03 | 1.26 |
| Max Drawdown (5Y) | -72.24% | -65.87% |
| Avg. Volume (3M) | 250.78K | 2.81M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | BIO | TECH |
|---|---|---|
| Sharpe Ratio (1Y) | 0.66 | 0.54 |
| Sortino Ratio (1Y) | 0.98 | 0.82 |
Profitability
ROE (TTM)
Both Bio-Rad Laboratories (BIO) at 14.27% and Bio-Techne (TECH) at 8.33% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
14.27%
- Max
- 109.18%
- BIO
- 14.27%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
TECH
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.33%
- Max
- 109.18%
- TECH
- 8.33%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Bio-Rad Laboratories (BIO) at 39.45% keeps the most of each sales dollar — above its industry’s net margin range — and Bio-Techne (TECH) at 14.00% also retains a top-quartile share.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
39.45%
- BIO
- 39.45%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
TECH
Pharmaceuticals, Biotechnology & Life Sciences industry group
14.00%
- Max
- 18.05%
- TECH
- 14.00%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Bio-Rad Laboratories (BIO) at 11.82% and Bio-Techne (TECH) at 12.21% run core operations about as efficiently as their industries’ norm — neither stands out on operating profitability.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
11.82%
- Max
- 83.12%
- Q3
- 14.77%
- BIO
- 11.82%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
TECH
Pharmaceuticals, Biotechnology & Life Sciences industry group
12.21%
- Max
- 83.12%
- Q3
- 14.77%
- TECH
- 12.21%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | BIO | TECH |
|---|---|---|
| ROE (TTM) | 14.27% | 8.33% |
| ROA (TTM) | 1.50% | 6.38% |
| Net Margin (TTM) | 39.45% | 14.00% |
| Operating Margin (TTM) | 11.82% | 12.21% |
| Gross Margin (TTM) | 52.19% | 66.23% |
Growth
Revenue Growth
Both Bio-Rad Laboratories (BIO) at 0.65% and Bio-Techne (TECH) at -0.38% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Only one side can be read here: Bio-Techne (TECH) reports EPS growth of 152.17%, ranked against its industry; Bio-Rad Laboratories (BIO) has no EPS growth figure this period.
Growth Metrics
| Metric | BIO | TECH |
|---|---|---|
| Revenue Growth (YoY) | 0.65% | -0.38% |
| Revenue Growth (3Y CAGR) | -2.68% | 2.25% |
| EPS Growth (YoY) | -- | 152.17% |
| EPS Growth (3Y CAGR) | -- | -12.97% |
Financial Strength
Current Ratio (MRQ)
Bio-Rad Laboratories (BIO) at 3.18 keeps current ratio within its industry’s typical mid-range, while Bio-Techne (TECH) at 2.28 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for TECH.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.18
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- BIO
- 3.18
- Q1
- 2.47
- Min
- 0.10
TECH
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.28
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- TECH
- 2.28
- Min
- 0.10
Debt / Equity (MRQ)
Both Bio-Rad Laboratories (BIO) at 0.18 and Bio-Techne (TECH) at 0.13 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.18
- Max
- 1.42
- Q3
- 0.65
- BIO
- 0.18
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
TECH
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.13
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- TECH
- 0.13
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | BIO | TECH |
|---|---|---|
| Current Ratio (MRQ) | 3.18 | 2.28 |
| Debt / Equity (MRQ) | 0.18 | 0.13 |
| Net Debt / EBITDA | -0.73 | -0.20 |
Dividends
Dividend Yield (TTM)
Bio-Rad Laboratories (BIO) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Bio-Techne (TECH) reports a yield of 0.44%, ranking against industry peers normally.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BIO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
TECH
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.44%
- TECH
- 0.44%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Bio-Rad Laboratories (BIO) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Bio-Techne (TECH) reports a payout of 27.59%, ranking against industry peers normally.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BIO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
TECH
Pharmaceuticals, Biotechnology & Life Sciences industry group
27.59%
- TECH
- 27.59%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | BIO | TECH |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.44% |
| Dividend Payout Ratio (TTM) | 0.00% | 27.59% |
Valuation
P/E Ratio (TTM)
Bio-Rad Laboratories (BIO) at 10.14 sits in the cheaper P/E ratio quartile, while Bio-Techne (TECH) at 62.74 sits in the richer quartile — a clear split in what investors pay for each dollar of trailing earnings.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
10.14
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- BIO
- 10.14
- Min
- 0.07
TECH
Pharmaceuticals, Biotechnology & Life Sciences industry group
62.74
- Max
- 85.34
- TECH
- 62.74
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Bio-Rad Laboratories (BIO) at 3.96 and Bio-Techne (TECH) at 9.31 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.96
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- BIO
- 3.96
- Q1
- 3.01
- Min
- 0.01
TECH
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.31
- Max
- 58.18
- Q3
- 25.77
- TECH
- 9.31
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Bio-Rad Laboratories (BIO) at 1.35 sits in the lower P/B ratio quartile against book while Bio-Techne (TECH) at 5.28 is valued near its industry’s middle — BIO is cheaper on assets, though weigh it against ROE and asset quality.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.35
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- BIO
- 1.35
- Min
- -5.59
TECH
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.28
- Max
- 13.53
- Q3
- 6.54
- TECH
- 5.28
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | BIO | TECH |
|---|---|---|
| P/E Ratio (TTM) | 10.14 | 62.74 |
| P/S Ratio (TTM) | 3.96 | 9.31 |
| P/B Ratio (MRQ) | 1.35 | 5.28 |
| Free Cash Flow Yield (TTM) | 2.65% | 2.39% |